A new generation rotavirus vaccine for children has been tested at the Gamaleya Center.

N. F. Gamalei NITSEM scientists have completed clinical trials of a new rotavirus vaccine involving children in the age group from nine months to six years. The developer has experimentally proven the safety and effectiveness of the drug. Experts expect to submit an application for registration for use among children of this age in June. Now they are starting the next stage of experiments involving children from eight to 32 weeks old. It is patients of this age who are the main target group for the vaccine.

"For older children, we are applying for registration in June. And with the end of the clinical trial in the target group, we will apply in September. We hope that we will receive registration for children of all ages. But when it happens, it's not just up to us. The Center of Expertise will review the application. I hope the vaccine will be introduced into civil circulation in 2026," Tatyana Grebennikova, head of the Laboratory of Molecular Diagnostics at the N. F. Gamaleya Federal Medical Research Center, told Izvestia.

A new remedy for rotavirus is a hexavalent vaccine. It includes six genotypes of the virus. After vaccination, the child develops antibodies against them, which also protect against two more genotypes due to cross-immunity. The new drug is specifically aimed at creating immunity against those variants of rotavirus that are characteristic of our country.

Read more in the exclusive Izvestia article:

People's stomachs: a new generation rotavirus vaccine for children has been tested at the Gamaleya center